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Introduction: Listeriosis is a food-borne disease of 
public health importance that has recently been 
involved in prolonged outbreaks. Despite its rele-
vance, listeriosis is under-reported in many European 
countries. Aim: We aimed to describe listeriosis epi-
demiology in Spain from 1997–2015. Methods: We 
performed a retrospective study using the Spanish 
hospitalisation database. We calculated the mean 
number of hospitalisations per year and region. 
Pregnancy and neonatal-related listeriosis rates were 
computed. Relation between death and the presence 
of underlying health conditions was explored. Results: 
Between 1997–2015, 5,696 listeriosis hospitalisa-
tions occurred, showing a constantly increasing trend. 
Higher hospitalisation rates were located in the north 
of the country compared to southern regions. The age 
group ≥ 65 years old was the most represented (50%). 
Pregnant women and newborns accounted for 7% and 
4% of hospitalisations, respectively. An underlying 
immunocompromising condition was present in 56.4% 
of patients: cancer (22.8%), diabetes mellitus (16.6%) 
and chronic liver disease (13.1%). Death occurred in 
17% of patients, more frequently among those ≥ 65 
years old (67.5%), with sepsis (39.9%) or with menin-
goencephalitis (19.2%). Conclusion: Listeriosis is an 
emergent public health problem in Spain that calls 
for targeted action. Further prevention strategies are 
urgently needed, including food safety education and 
messaging for all at-risk groups.
Introduction
Listeriosis is an infectious disease caused by bacteria 
of the genus Listeria spp. L. monocytogenes is the major 
pathogenic species in both animals and humans.  L. 
monocytogenes  is a Gram-positive, rod-shaped organ-
ism that can grow in aerobic and anaerobic conditions 
[1], is widely distributed in the environment and is able 
to contaminate a wide variety of foods or beverages 
(soft cheese, deli meats, unpasteurised milk, refrig-
erated smoked seafood, etc.) [2]. The bacteria can 
multiply at refrigerator temperatures [3]; therefore, 
contaminated products are often kept for several days 
or even weeks, e.g. in the household/restaurants, and 
may be eaten on multiple occasions, which can compli-
cate the identification of the incriminated food source 
[4].
The clinical syndromes of listeriosis include: febrile 
gastroenteritis, sepsis, central nervous system (CNS) 
involvement in the form of encephalitis, meningoen-
cephalitis and focal infections such as pneumonia 
myo-endocarditis and septic arthritis, etc [5]. Invasive 
listeriosis most commonly affects pregnant women, 
neonates, elderly people and people with chronic con-
ditions or weakened immune response [6]. Listeriosis 
has one of the highest case fatality rates among all 
food-borne infections; when it affects the CNS, the mor-
tality rate is above 50% and neurological sequelae are 
present in more than 60% of survivors [2]. Listeriosis is 
also associated with fetal and neonatal death.
Worldwide, listeriosis is an emerging infection of 
public health concern [7]. In Europe, human listeri-
osis peaked in incidence during the 1980s, showed a 
general decline during the 1990s and stabilised in the 
2000s [8]. More recent data show an increasing trend 
since 2008 [9]. This increase seems to be related to 
the ageing of the population and the increase in life 
expectancy of immunocompromised patients, but also 
to changes in the ways food is produced, stored, dis-
tributed and consumed around the world [10]. Although 
listeriosis is often a sporadic disease [11], large food-
borne outbreaks have occurred during the last decade 
in Europe and the United States (US) [12]. In South 
Africa, an outbreak with more than 1,024 laboratory-
confirmed listeriosis cases, as at 2 May 2018, has been 
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ongoing since the start of 2017, with a 28.6% case 
fatality rate [13].
In Spain, food safety criteria (FSC) for  L. monocy-
togenes  follow European Commission (EC) regulations 
[14,15]. Before 2015, when it was added to the list of 
mandatory notifiable diseases, regions could voluntar-
ily report listeriosis to the Microbiological Information 
System (Sistema de Información Microbiológica, SIM) 
[16]. Using the centralised hospital discharge database 
(Conjunto Mínimo Básico de Datos, CMBD), we aimed 




Using the CMBD database, we performed a retro-
spective descriptive study of listeriosis epidemiology 
between 1 January 1997–31 December 2015. The CMBD 
database receives notifications from around 98% of 
the public hospitals in Spain [17]. The National Health 
System (NHS) provides free medical care to 99.5% of 
the Spanish population; however, those who are not 
covered by the NHS can also be treated at public hospi-
tals [18]. For this study, the International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) was used [19]. The case definition was a patient 
with ICD-9-CM diagnostic listeriosis (ICD-9 code: 
027.0), placed in any diagnostic position. Relevant 
underlying conditions were also explored by search-
ing for all related conditions in any diagnostic position. 
According to the literature, some of these conditions 
are malignant neoplasm (ICD-9 code: 140–209), dia-
betes mellitus (ICD-9 code: 250), chronic liver disease 
(ICD-9 code: 571), HIV infection (ICD-9 code: 042) and 
other immunosuppressive condition (ICD-9 code: 279).
In order to assess temporal and geographical patterns, 
the average number of hospitalisations per year and 
region (Comunidad Autónoma, CC.AA) were calculated. 
The population figures from the National Statistics 
Institute (Instituto Nacional de Estadística, INE) web-
site were used to determine the population at risk [20]. 
Mortality data and live birth statistics, available since 
1998, were also obtained from the INE website. To esti-
mate the number of pregnant women, the following 
previously published method was applied: the fertility 
rate was multiplied by nine-twelfths of the population 
of women of reproductive age, since pregnancy lasts 
an average of 9 months. Similarly, the abortion/miscar-
riage rate was multiplied by a sixth of the population 
of women of reproductive age, since abortion usually 
occurs after 2 months of pregnancy. These two num-
bers were added to estimate the number of women who 
were pregnant per year during the study period [21].
Hospitalisation trends were assessed by age group and 
region. Results in terms of mean rates by CC.AA were 
plotted on maps using the Geographical Information 
System QGis free software version 2.18.13 (QGIS 
Development Team).
Socio-demographic and clinical data were extracted 
from the CMBD. Age was categorised in four 
groups: ≤ 15, 16–44, 45–64 and ≥ 65 years old, to pro-
vide an overview of children, young adults, older adults 
and elderly people. Hospitalisation costs were calcu-
lated using diagnostic cost groups based on diagno-
sis-related groups (DRGs) for hospitalised patients and 
their age, sex and resource consumption. DRGs repre-
sent a medical-economic entity, i.e. a set of diseases 
requiring analogous management resources [22].
Frequencies and percentages were used to summarise 
data. The association between related health condi-
tions and death was assessed using a chi-squared 
test. Logistic regression models were obtained using 
a manual backward stepwise procedure and risk ratios 
(RRs) were computed with 95% confidence intervals 
(CI). Age was included as an adjustment variable and 
p values < 0.05 were considered statistically significant. 
Data analysis was performed using STATA software 
version 14 (StataCorp LLC, College Station, US).
Ethical statement
This study involves the use of patient medical data from 
the CMBD. These data are hosted by the Ministry of 
Health, Consumer Affairs and Social Welfare (MSCBS). 
Researchers working in public and private institutions 
can request access to the database by filling in and 
signing a questionnaire available on the MSCBS web-
site. In this questionnaire, a signed confidentiality 
commitment is required. All data are anonymised and 
de-identified by the MSCBS before it is made available 
to applicants [17].
Results
Spatial and temporal trends in Spain
Between 1997–2015, there were 5,696 hospitalisa-
tions with diagnosis of listeriosis in any diagnostic 
position recorded in the CMBD database. The ICD-9 
code for listeriosis was positioned as first diagnosis 
in 3,110 (54.6%) of all such hospitalisations and as 
second diagnosis in 1,802 (31.6%). The mean listeri-
osis hospitalisation rate for the study period was 0.67 
per 100,000 population (range: 0.19 in 1997 to 1.01 in 
2013), with an increasing trend over the study period 
(p = 0.017).
When comparing listeriosis hospitalisation rates by age 
group, relevant and significant differences emerged 
(p < 0.05). The age group ≥ 65 years old showed the high-
est rate, followed by 45–64 year olds. For those ≥ 65 
years old, the mean hospitalisation rate in 2004–15 
was more than twice that of the previous period: 2.48 
vs 1.09 per 100,000 population, respectively (Figure 1).
 
Regarding the regional distribution, most CC.AA with 
higher hospitalisation rates were located in the north 
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of the country. Catalonia had the highest incidence 
rates of listeriosis hospitalisations (23.19 hospitali-
sations/100,000 population), followed by Cantabria 
(18.87/100,000 population), Rioja (17.09/100,000 pop-
ulation), Basque country (17.03/100,000 population) 
and Galicia (14.82/100,000 population) (Figure 2).
Socio-demographic characteristics and clinical 
features of listeriosis-related hospitalisations
The mean age of the 5,696 listeriosis-hospitalised 
patients was 58.6 years, with a median value of 64.5 
years (Interquartile range (IQR): 47–75). Of those hospi-
talised, 59% were male (Table 1). The median age was 
66 years (IQR: 53–75) in men and 61 years (IQR: 35–76) 
in women. As shown in  Figure 1, the age group ≥ 65 
years old was the most represented (50%). Males pre-
dominated in the age groups 45–64 years old (68.1%) 
and ≥ 65 years old (63%), while females represented 
64.6% of those 15–44 years old (Figure 3; p < 0.01).
Certain parallels were observed between the increase 
in the number of people ≥ 65 years old who were hos-
pitalised for listeriosis and the increase in life expec-
tancy in Spain during the same period (Supplementary 
Figure 1).
The average length of hospital stay for listeriosis was 
21.4 days. We found a wide range for the hospitalisa-
tion costs, with a median value of EUR 6,327 per case 
(IQR:  4,680–6,858), with no significant changes over 
time (Table 1).
Meningoencephalitis and/or septicaemia was seen in 
43.3% and 8% of listeriosis hospitalisations, respec-
tively. Males developed meningoencephalitis more 
often than women (47.4% vs 37.3%; p < 0.01). No differ-
ences were observed between males and females for 
septicaemia. Meningoencephalitis was more frequent 
among the age group 45–64 years old (50.1%), while 
those  ≥ 65 years old were more likely to have devel-
oped septicaemia (9.2%; p < 0.01).
Fatal outcome occurred in 17% of all listeriosis hospital-
isations. The mean mortality rate was 0.06 per 100,000 
population. Patients aged ≥ 65 years old accounted for 
67.5% of deaths (p < 0.001). Fatal outcome happened in 
19.2% of meningoencephalitis (RR: 1.26; 95% CI: 1.12–
1.41; p < 0.01) and 39.9% of patients with septicaemia 
(RR: 2.66; 95% CI: 2.34–3.03; p < 0.01).
Pregnancy-related listeriosis and neonatal 
listeriosis
Pregnant women accounted for 7% (n = 396) of listeri-
osis hospitalisations. The mean infection rate during 
pregnancy was 7.19 per 100,000 pregnant women, 
showing several peaks (Figure 4) and a significant 
increase during the study period. No fatal outcomes 
were registered among pregnant women (p < 0.001).
 
Neonatal infections represented 4% (n = 225) of the 
overall listeriosis hospitalisations. The mean neonatal 
infection rate for the study period was 2.75 per 100,000 
Figure 1
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live births, indicating an increase from 1998–2007 (no 
cases were registered in 1997). This was followed by a 
steady decline in 2008–09, an increase from 2010–14 
and finally a steady decline from 2015. Fatal outcome 
was less frequent in infected neonates than in the 
overall population (8.9% vs 17.3%; p < 0.01).
Immunodeficiency-related listeriosis
Underlying immunocompromising conditions were 
observed in 56.4% (3,213/5,696) of the hospitalised 
patients: malignant neoplasm (n = 1,298; 22.8%), dia-
betes (n = 943; 16.6%), chronic liver disease (n = 747; 
13.1%), HIV infection (n  =  151; 2.7%) and other immu-
nocompromising conditions (n = 69; 1.2%). Within the 
malignant neoplasm group, particularly frequent diag-
noses were secondary malignant neoplasm (n  =  480; 
8.4%; ICD-9: 196–198), malignant neoplasm of tra-
chea bronchus and lung (n  =  164; 2.9%; ICD-9: 162), 
lymphoid leukaemia (n = 146; 2.6%; ICD-9: 204), other 
malignant neoplasms of lymphoid and histiocytic tis-
sue (n  =  132; 2.3%; ICD-9: 202), malignant neoplasm 
of colon (n = 94; 1.7%; ICD-9: 153) and malignant neo-
plasm of liver and intrahepatic bile ducts (n = 67; 1.3%; 
ICD-9: 155).
Hospitalised patients aged ≥ 65 years old were more 
likely to have malignant neoplasm and/or diabetes 
mellitus (p < 0.01), while chronic liver disease was more 
frequent in patients 45–64 years old (45.9%; p < 0.01). 
HIV-related listeriosis in 15–44 year old patients 
accounted for 55% of the listeriosis-hospitalised 
patients with HIV (p < 0.01).
Relation between fatal outcome and the presence 
of an underlying health condition was explored and 
adjusted by age. Fatal outcome occurred more fre-
quently in hospitalised patients with listeriosis and co-
diagnosis of diabetes mellitus (adjusted RR: 1.33; 95% 
CI: 1.10–1.60) and/or malignant neoplasm (aRR: 1.90; 
95% CI: 1.63–2.22). Among the most prevalent malig-
nant neoplasms, only secondary malignant neoplasm 
and malignant neoplasm of trachea, bronchus and lung 
increased the risk of death (Table 2).
Discussion
This study provides a 19-year review of listeriosis 
hospitalisations in Spain. To date, the few articles 
that have been published on listeriosis epidemiology 
in Spain were focused on outbreak investigations or 
based on incomplete information sources [23-25]. To 
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our knowledge, this is the first study to address listeri-
osis epidemiology nationwide.
Between 1997–2015, a total of 5,696 listeriosis-related 
hospitalisations occurred in Spain. From 2009–13, 
there were 588 listeriosis cases reported to SIM, the 
European Surveillance System (TESSy) and the cor-
responding yearly European Food Safety Authority 
(EFSA) reports [26]; however, 2,051 listeriosis-related 
hospitalisations were recorded in the CMBD, indicat-
ing considerable under-reporting. Even if this indicates 
that the epidemiological scenario is quite uncertain, 
in 2012 the Spanish listeriosis rate reported to EFSA 
was the second highest of any country in the European 
Union (EU) (0.93, vs an EU-wide incidence rate of 
0.41/100,000 population) [27]; this indicates that more 
attention needs to be given to preventing and control-
ling this disease in Spain.
Our results suggest an increasing trend of listeriosis 
infection in Spain during the study period (1997–2015). 
In the last decade, listeriosis incidence rates have 
increased or remained stable at relatively high lev-
els across Europe. Despite the application of the FSC 
for L. monocytogenes  in ready-to-eat (RTE) foods from 
2006 onwards, a statistically significant increasing 
trend of human invasive listeriosis has been reported 
in the EU/European Economic Area (EEA) from 2009–13 
[28]. From 2012–16, between 1,754 and 2,555 L. mono-
cytogenes  cases were reported annually to TESSy by 
30 EU/EEA countries [3]. In the absence of systematic 
and national surveillance in several European coun-
tries, under-reporting may be masking an even worse 
scenario. In Spain, listeriosis became a mandatory 
Table 1






≤ 15 373 6.5
15–44 943 16.6
45–64 1,532 26.9








Variables Mean Median IQR
Age (years) 58.6 64.5 47–75
Hospitalisation length of stay 
(days) 21.4 17 9–26
Hospitalisation cost (Euros) 38,157 6,327 4,680–6,858
IQR: interquartile range.
Figure 3
Number of listeriosis hospitalisations by sex and age 
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notifiable disease in 2015 [29]. As demonstrated in the 
Netherlands, public health investment in surveillance 
can yield an increase in reported cases of listeriosis 
[30]; therefore, an increase in listeriosis detection may 
be expected in the future.
The increasing proportion of susceptible persons in the 
general population is a feasible contributing factor to 
this increased incidence [31]. In our study, listeriosis 
rates increased mostly in those ≥ 65 years old; accord-
ing to the 2015 EFSA report, the proportion of cases in 
this age group steadily increased from 56% in 2008 to 
64% in 2015 [9], which is similar to our results.
Another potential contributing factor to the overall 
increase in listeriosis is the rise in consumption of RTE 
foods. European surveys have revealed associations 
between listeriosis and several parameters, including 
food packaging types, preparation practices and stor-
age temperatures; the stage of sampling with respect 
to shelf life; and a lack of education and training of 
food handlers [11].
The emergence of particularly virulent strains 
of  Listeria  spp. is also of concern for public health. It 
has been demonstrated that  L. monocytogenes  can 
exhibit tolerance to quaternary ammonium disinfect-
ants, as well as temperature-dependent resistance to 
phages, which can be gained through acquisition of 
new genes as well as mutations in existing genes [32] 
Moreover, it seems that differences among strains have 
an impact on virulence of specific immunocompromised 
subpopulations [8]. Another possible explanation is 
the increased consumption of drugs that reduce gastric 
acidity. In humans, the low pH of the stomach provides 
a significant barrier to Listeria spp. infection and it has 
been demonstrated that patients taking medications 
that reduce gastric acid (like proton pump inhibitors 
(PPI)) are at increased risk of infection [33]. In 2010, 
PPI became the most commonly consumed active com-
pound in Spain, in terms of number of packages sold. 
In fact, in comparison to other European countries, 
Spain leads gastric anti-secretory drug consumption 
with the number of prescriptions soaring 70% over the 
European average [34].
During the study period, only a few listeriosis out-
breaks in Spain were reported in the literature, mostly 
in the Basque country. These outbreaks were related to 
the consumption of Latin-style fresh cheese made from 
pasteurised milk in Portugal [35] and cooked ham [36]. 
In both situations, health professionals were informed 
and were recommended to strongly consider the diag-
nosis of listeriosis in high-risk individuals. Genetic 
studies also revealed the occurrence of an outbreak 
in Castilla-Leon, which was unreported and thus the 
source of the outbreak was not traced [37]. Several 
outbreaks due to the consumption of ‘vegetables and 
juices and other products thereof’ were also reported 
to EFSA during 2010–16 [3]. Furthermore, the preva-
lence of L. monocytogenes  in RTE products in markets 
in northern Spain was recently studied, finding that 
smoked fish was the most frequently contaminated 
food category [38]. These findings and the outbreaks 
mentioned above influenced Spain’s change to man-
datory national reporting of listeriosis cases in 2015 
[16]. The Spanish Agency for Consumer Affairs, Food 
Safety and Nutrition (Agencia Española de Seguridad 
Alimentaria y Nutrición) receives several notifica-
tions every year and informs the regional authorities 
via the national Food Alert Network and the European 
Commission Services via the Rapid Alert System for 
Food and Feed; at the national level, contaminated 
products are recalled from markets [39]. It is nev-
ertheless possible that additional outbreaks and/or 
clusters may have gone unnoticed due to the lack of 
surveillance.
Improvements in listeriosis surveillance (including 
accurate microbiological investigations) with active 
collaboration between public health officials and food 
regulatory officials should improve the situation. Data 
sharing at the European level is also essential, given 
that many food-borne disease outbreaks happen in a 
multi-country setting [3]. Without further action, yearly 
numbers are likely to continue to grow, for the afore-
mentioned reasons.
We found relevant disparities between regions, with 
higher hospitalisation rates mostly in the north of the 
country. This might be due to differences in dietary hab-
its, food consumption or regulations; the population’s 
average age; differences in educational preventive 
measures and/or that health professionals are more 
prone to seek listeriosis diagnosis. However, further 
investigation is needed to confirm these hypotheses.
In this study, we found that from 1997–2015 Listeria spp. 
infection in Spain was more common among males. The 
Figure 4
Listeriosis hospitalisation rates in pregnant women and 
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origin of the sex preference of L. monocytogenes infec-
tion has not yet been clarified, but it seems to be 
related to susceptibility to infection, as demonstrated 
for other infectious diseases [40]. The highest hospi-
talisation rate for both sexes was seen in the ≥ 65 age 
group, with a higher rate for males than for females. 
However, females accounted for more hospitalisations 
in the age group 15–44, which is believed to largely 
reflect pregnancy-related listeriosis. The mean length 
of hospital stay and associated costs, including for 
those individuals who ultimately died as a result of 
their infections, were quite high, close to those in an 
outbreak in Canada [41]. In a study carried out in the 
Netherlands, perinatal listeriosis accounted for the 
highest cost-of-illness per infected case among the 14 
most frequent food-related pathogens [42].
Death occurred in 17% of the listeriosis hospitalisa-
tions observed in this study. In the literature, the over-
all listeriosis mortality rate ranged from 20–30% [43], 
a bit higher than the rate we encountered. Considering 
that we only analysed hospitalised patients, the 
opposite should have been expected. Nevertheless, 
non-invasive listeriosis cases were also identified. In 
fact, fatal outcome in listeriosis hospitalisations was 
significantly associated with being ≥ 65 years old, the 
Table 2
Related health conditions and fatal outcome in listeriosis hospitalisations, Spain, 1997–2015 (n = 5,696)
Related health conditions
Death
RR 95% CI aRR 95% CINo Yes




Yes 950 73.19 348 26.81
1.90 1.69–2.13* 1.90 1.63–2.22*




Yes 317 66.04 163 33.96
2.20 1.91–2.53* 2.61 2.12–3.21*






Yes 104 63.41 60 36.59
2.22 1.81–2.75* 2.59 1.86–3.60*
No 4,624 83.59 908 16.41
Lymphoid 
leukaemia
Yes 121 82.88 25 17.12
1.00 0.70–1.45 0.85 0.55–1.32






Yes 100 75.76 32 24.24
1.44 1.06–1.96* 1.36 0.90–2.05




Yes 73 77.66 21 22.34
1.32 0.90–1.94 1.12 0.69–1.84
No 4,655 83.10 947 16.90
Malignant 
neoplasm 
of liver and 
intrahepatic 
bile ducts
Yes 49 73.13 18 26.87
1.59 1.07–2.37* 1.43 0.83–2.48
No 4,679 83.12 950 16.88
HIV infection
Yes 129 85.43 22 14.57
0.85 0.58–1.26 1.49 0.93–2.41**
No 4,599 82.94 946 17.06
Diabetes mellitus
Yes 781 82.82 162 17.18
1.01 0.87–1.18 1.33 1.10–1.60*
No 3,947 83.04 806 16.96
Chronic liver diseases
Yes 603 80.72 144 19.28
1.16 0.99–1.36** 1.13 0.92–1.38
No 4,125 83.35 824 16.65
aRR: adjusted risk ratio; CI: confidence interval; RR: relative risk.
* p < 0.05; **p < 0.10.
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presence of meningoencephalitis or septicaemia, and 
some underlying conditions.
An increasing trend in listeriosis hospitalisation rate 
was observed in pregnant women. According to a 
recent EFSA report, listeriosis cases in Europe have 
increased among women aged 25–44. It is believed that 
these cases are mainly pregnancy related [28]. In the 
US and France, the incidence of listeriosis in pregnant 
women declined in the 1990s after the implementation 
of industrial, regulatory and educational measures. 
Moreover, the incidence of pregnancy-related listeri-
osis was lower in French regions with a low preva-
lence of toxoplasmosis [44], which may be related to 
differences in educational measures to prevent both 
diseases. In Spain, there is currently no screening for 
listeriosis during pregnancy, nor specific dietary rec-
ommendations for pregnant women [45]; therefore, 
dietary recommendations and screening activities dur-
ing pregnancy should be introduced.
Malignant neoplasm, mostly hematologic disease, was 
observed in 22.8% of listeriosis-related hospitalisa-
tions. Cancer and immunosuppressive therapy were 
among the most frequently recorded comorbid condi-
tions in non-pregnancy–associated cases of listeriosis, 
mainly due to impaired cell-mediated immunity and 
other underlying conditions [5]. Moreover, the mortal-
ity rate of  L. monocytogenes  infection is elevated in 
cancer patients, as infections can be more difficult and 
time consuming to treat [46]. Secondary malignant neo-
plasm and malignant neoplasm of trachea, bronchus 
and lung were the malignant neoplasms with the high-
est probability of fatal outcome. In a review of listeri-
osis cases reported in France from 2001–08, patients 
with lung and pancreatic cancer had the highest case 
fatality rate of listeriosis [47].
Fatal outcome also occurred more frequently in hos-
pitalised patients with chronic liver diseases and/or 
diabetes mellitus, although statistical difference only 
remained significant for diabetes mellitus after adjust-
ment by age. According to a review of listeriosis cases 
worldwide, patients with cancer and type 2 diabetes 
mellitus have five times the risk of contracting listerio-
sis [48]. Diabetes mellitus may lead to an immunocom-
promised state by decreased efficacy of cell-mediated 
immunity; for example, diabetic patients are twice as 
susceptible to bacterial meningitis as patients who 
are not diabetic [49]. Moreover, patients with diabetes 
may have additional immunocompromising conditions. 
Health professionals should be aware of this and spe-
cific food recommendations should be given to these 
patients, together with other public health general 
interventions.
Limitations and conclusions
Our study has several limitations. Even if the CMBD pro-
vide information from a network of hospitals that covers 
more than 99% of the population in Spain [13], hospital 
discharge records do not include cases managed in an 
outpatient setting or asymptomatic cases; thus, hospi-
tal records underestimate the real burden of listeriosis 
in Spain. Moreover, the CMBD does not provide infor-
mation about the laboratory tests used for listeriosis 
diagnosis, which impairs the quality of the data. Also, 
we could not identify mother-baby pairs, as the per-
sonal information necessary to do this is missing from 
this database due to data protection.
In conclusion, our report highlights that listeriosis 
is an important public health problem in Spain that 
needs to be prioritised, especially due to its increasing 
trend and severity. Listeriosis surveillance needs to be 
improved and further targeted prevention is urgently 
needed, including food safety education and messag-
ing in all at-risk groups. Implementing, for example, 
the US Centre for Disease Control’s recommendations 
for the prevention of listeriosis for the general pub-
lic—especially high-risk populations—may be a start-
ing point [25]. Furthermore, industrial and regulatory 
measures needs to be implemented in parallel, as an 
integrated and multi-sectoral approach is the only way 
to successfully prevent and control listeriosis.
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